...
机译:单独的氟纤维和2氟纤维的1和2研究,并与低剂量地塞米松的复发/难以多发性骨髓瘤组合
Department of Lymphoma/MyelomaThe University of Texas MD Anderson Cancer CenterHouston Texas;
Winship Cancer InstituteEmory University School of MedicineAtlanta Georgia;
Barbara Ann Karmanos Cancer InstituteWayne State UniversityDetroit Michigan;
Fox Chase Cancer CenterPhiladelphia Pennsylvania;
Fred Hutchinson Cancer Research CenterSeattle Washington;
Array BioPharma IncBoulder Colorado;
Array BioPharma IncBoulder Colorado;
Array BioPharma IncBoulder Colorado;
Array BioPharma IncBoulder Colorado;
Array BioPharma IncBoulder Colorado;
Array BioPharma IncBoulder Colorado;
Department of Lymphoma/MyelomaThe University of Texas MD Anderson Cancer CenterHouston Texas;
Winship Cancer InstituteEmory University School of MedicineAtlanta Georgia;
dexamethasone; filanesib. kinesin; maximum tolerated dose; multiple myeloma; pharmacokinetics; spindle poles;
机译:单独的氟纤维和2氟纤维的1和2研究,并与低剂量地塞米松的复发/难以多发性骨髓瘤组合
机译:MM-003肾病的分析,这是pomalidomide +低剂量地塞米松与高剂量地塞米松对难治性或复发性和难治性多发性骨髓瘤的III期研究
机译:Isatuximab加上氯胺和低剂量的地塞米松与氯胺和低剂量的地塞米松,患者复发和难治性多骨髓瘤(icaria-mm):一个随机的,多型,开放标签,第3期研究
机译:沙利度胺加上难治性/复发患者中的中间剂量地塞米松
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:费拉尼昔单独或与小剂量地塞米松联用治疗复发/难治性多发性骨髓瘤的1/2期研究
机译:I50067的I相剂量升级研究,单独的人源化抗CXCR4单克隆抗体,并与Lenalidomide和低剂量地塞米松组合,复发或难治多骨髓瘤